ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion: new indication

Secukinumab (Cosentyx)

Adolescent hidradenitis suppurativa (HS) Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents 12 years and older with an inadequate response to conventional systemic HS therapy (see section 5.1).

CHMP opinion 12 Nov 2026 · Novartis Europharm Limited

Research

Rheumatology · Lancet Rheumatol · 2026-06-29

In 502 adults with moderate-to-severe plaque psoriasis, biosimilar BAT2306 was equivalent to reference secukinumab for percentage PASI change at week 8 (difference 1·549) and week 12 (−0·349), within all regulatory margins; safety and immunogenicity were comparable.

RCTn = 502
Chen et al. Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial
Dermatology · Lancet · 2023-02-03

In two phase 3 trials in moderate-to-severe hidradenitis suppurativa, secukinumab every 2 weeks improved week-16 clinical response vs placebo (45% vs 34%; 42% vs 31%); every 4 weeks was significant only in SUNRISE (46% vs 31%), not SUNSHINE (42% vs 34%).

RCTn = 1,084
Kimball et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.